Our findings support CEA as a prognostic biomarker for pathological response after neoadjuvant therapy in rectal cancer and confirm that total neoadjuvant therapy is associated with higher rates of pCR and favorable tumor regression. The gene discussed is CEACAM5; the disease is rectal cancer.